|
Paul J. Schechter, M.D., Ph.D. has been our Vice President, Drug Development & Regulatory Affairs and Chief Medical Officer since May 2002. From 1998 to April 2002, he served as a Vice President of MacroChem Corporation, a drug delivery company. Prior to 1998, he held senior research and drug development positions at Fujisawa Pharmaceutical Company, Hybridon, Inc., a biotechnology company, and Merrell Dow, a pharmaceutical company, where he guided a number of new chemical entities through Phase 1, 2 and 3 clinical trials to regulatory approval. He has published more than 140 papers in the fields of biochemistry, pharmacology, pharmacokinetics, drug metabolism and clinical medicine and has seven U.S. published patents. Dr. Schechter began his career at the National Institutes of Health in Bethesda, Maryland and has been elected to membership in numerous professional societies in the United States and abroad. Dr. Schechter received his M.D. and Ph.D. in Pharmacology from the University of Chicago. Dr. Schechter resides in Dover, Massachusetts. | 